Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment

Yeğin, Ender Güneş; Oymacı, Erkan; Karatay, Emrah; Çöker, Ahmet

doi:10.1016/s1499-3872(16)60097-8

Cited by 45 publications

(32 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Residual liver function is an important determinator of the extent of liver resection for HCC . In the present study, prevention of intrahepatic recurrence was found to be proportional to the amount of liver parenchyma removed.…”

Section: Discussionsupporting

confidence: 52%

“…Although surgical resection is considered as the first‐line therapy for the management of single nodular hepatocellular carcinoma (HCC), intrahepatic recurrences are common and constitute the major cause of management failure even after curative surgery . Two underlying modes of intrahepatic recurrence have been suggested, that is, de novo or multicentric occurrence and intrahepatic metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution

Kim

Lee

Shin

et al. 2018

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Introductionmentioning

confidence: 99%

Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution

Kim

Lee

Shin

et al. 2018

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…The high lethality of HCC, a cancer of increasing incidence [2], stems from late-stage presentation and high prevalence of concomitant liver dysfunction [3]. Curative approaches (liver resection, ablation) in early-stage HCC are affected by high recurrence rates [4] and transplantation is feasible only within rigorous oncological criteria [5]. As cancer and liver dysfunction progress, loco-regional and systemic therapy may improve patients' survival.…”

Section: Introductionmentioning

confidence: 99%

Immune-based therapies for hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

show abstract

“…Owing to the high mortality and poor prognosis, HCC management and treatment have been widely researched. In the recent decade, although there are some advancements in the surgical treatment or antineoplastic drugs for HCC, the prognosis has not significantly improved . Tumour recurrence and metastasis are the main causes of poor prognosis or even death for HCC patients.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA 91H overexpression contributes to the growth and metastasis of HCC by epigenetically positively regulating IGF2 expression

Wang

Shi

et al. 2019

Liver International

View full text Add to dashboard Cite

are contributed equally to this work.Abbreviations: ChIP, Chromatin immunoprecipitation; H3K27me3, H3 lysine 27 trimethylation; H3K4me3, H3 lysine 4 trimethylation; HCC, Hepatocellular carcinoma; IGF2, Insulin-like growth factor 2; lncRNAs, Long noncoding RNAs; MANT, the matched adjacent nontumourous tissues; MTT, the methyl thiazolyl tetrazolium; NALT, the normal adult liver tissues;Neg-ctrl, negative control cells; PI, propidium iodide; PRC2, polycomb repressive complex 2; RIP, the RNA immunoprecipitation; sh91H, 91H shRNA; si91H, 91H siRNA; siRBBP5, RBBP5 siRNA; TEPV, tumour embolus of portal vein; TrxG, Trithorax group. AbstractBackground & Aims: Long noncoding RNA 91H is transcribed from the H19/IGF2 locus and contributes to the development of breast and oesophagus cancers by regulating the expression of IGF2, but the regulation mechanism remains poorly characterized. Here, we explored the role of 91H in hepatocellular carcinoma (HCC) and the mechanism of IGF2 expression regulation by 91H.Methods: Firstly, the expression of 91H was analysed in HCC by quantitative RT-PCR, the association of 91H with survival was evaluated by the Kaplan-Meier method and the effect of 91H on the growth and invasion of HCC was investigated by the in vitro and in vivo studies. Then, the association of 91H with the expression of IGF2 was evaluated in HCC tissues, and the effect of 91H on the expression of IGF2 was investigated by 91H knockdown. Finally, the binding of RBBP5 to 91H and the binding of RBBP5, activating H3K4me3 mark and repressive H3K27me3 mark to the P3 and P4 promoters of IGF2 gene were studied by RIP and ChIP respectively. Results:The overexpression of 91H was found in HCC and in association with the growth, metastasis and shorter survival time of HCC. The knockdown of 91H downregulated the IGF2 expression in HCC, and the mechanism was correlated with the decreased enrichment of RBBP5 and H3K4me3 and increased enrichment of H3K27me3 at the bivalent P3 and P4 promoters. Conclusions:The overexpression of 91H promotes tumour growth and metastasis, and is associated with a poor prognosis of HCC at least partially by positively regulating the expression of IGF2 through bivalent histone modification changes characterized by H3K4me3 and H3K27me3 at the P3 and P4 promoters. K E Y W O R D S 91H, bivalent histone modifications, hepatocellular carcinoma, IGF2, Long noncoding RNA | 457 YI et al.

show abstract

Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment

Cited by 45 publications

References 221 publications

Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution

Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution

Immune-based therapies for hepatocellular carcinoma

Long noncoding RNA 91H overexpression contributes to the growth and metastasis of HCC by epigenetically positively regulating IGF2 expression

Contact Info

Product

Resources

About